JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mclean, R. A.
Right arrow Articles by Ullyot, G. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mclean, R. A.
Right arrow Articles by Ullyot, G. E.
Journal of Pharmacology And Experimental Therapeutics, Vol. 129, Issue 1, 17-23, 1960
Copyright © 1960 by American Society for Pharmacology and Experimental Therapeutics

PHARMACOLOGY OF TRIMETHYL [2-(2,6-DIMETHYLPHENOXY)PROPYL]-TRIMETHYLAMMONIUM CHLORIDE, MONOHYDRATE; COMPOUND 6890 OR betaTM 10

R. A. Mclean 1, R. J. Geus 1, J. Pasternack 1, P. A. Mattis 1, and G. E. Ullyot 1

1 Research and Development Division, Smith, Kline & French Laboratories, Philadelphia, Pennsylvania

Compound 6890, [2-(2,6-dimethylphenoxy) propyl]-trimethylammonium chloride monohy-drate or betaTM 10 has been shown able to lower blood pressure and reduce heart rate in laboratory animals.

These effects were seen in acute tests on anesthetized cats and dogs. They were also obtainable with long-term administration in unanesthetized animals.

Pressor reflexes such as those following carotid artery occlusion or afferent vagal faradization were inhibited by 6890.

A mode of action resembling that outlined for TM 10 by Exley (1957) was established for this analog. Its unique blocking effect seems to be selective for sympathetic nerve endings.

Acute and 30-day toxicity tests did not reveal any histopathology or blood dyscrasia.

Clinical trial of 6890 against hypertension and peripheral vascular disease in man should add to our understanding of the basic mechanisms responsible for these conditions.

Submitted on October 10, 1959






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1960 by the American Society for Pharmacology and Experimental Therapeutics.